Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models

Cancer Immunology, Immunotherapy

Volumn 65, Issue 8, 2016, Pages 885-896

  Guy, Thomas V ^a,b   Terry, Alexandra M ^a,b   Bolton, Holly A ^a,b   Hancock, David G ^a,b   Shklovskaya, Elena ^a,b   Fazekas de St Groth, Barbara ^a,b  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibodies; B cells; Clinical correlations; Tumour models

Indexed keywords

B LYMPHOCYTE ANTIBODY; CANCER ANTIBODY; IMMUNOGLOBULIN; TUMOR REACTIVE ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; B LYMPHOCYTE; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENIC ACTIVITY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; ANIMAL; DISEASE MODEL; IMMUNOLOGY; MOUSE; NEOPLASM;

ANIMALS; ANTIBODIES; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS;

EID: 84969972161     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1848-z     Document Type: Review

References (79)

1. Silina K, Rulle U, Kalnina Z, Line A (2014) Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue? Cancer Immunol Immunother 63(7):643–662. doi:10.1007/s00262-014-1544-9
2. Serre K, Cunningham AF, Coughlan RE, Lino AC, Rot A, Hub E, Moser K, Manz R, Ferraro A, Bird R, Toellner KM, Demengeot J, MacLennan IC, Mohr E (2012) CD8 T cells induce T-bet-dependent migration toward CXCR3 ligands by differentiated B cells produced during responses to alum-protein vaccines. Blood 120(23):4552–4559. doi:10.1182/blood-2012-03-417733
3. Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D (2014) T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346(6205):98–101. doi:10.1126/science.1254536
4. Ladanyi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejos Z, Gaudi I, Dobos J, Timar J (2011) Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 60(12):1729–1738. doi:10.1007/s00262-011-1071-x
5. + T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma. BMC Cancer 9:292. doi:10.1186/1471-2407-9-292
6. + T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18(12):3281–3292. doi:10.1158/1078-0432.CCR-12-0234
7. Shimabukuro-Vornhagen A, Schlosser HA, Gryschok L, Malcher J, Wennhold K, Garcia-Marquez M, Herbold T, Neuhaus LS, Becker HJ, Fiedler A, Scherwitz P, Koslowsky T, Hake R, Stippel DL, Holscher AH, Eidt S, Hallek M, Theurich S, von Bergwelt-Baildon MS (2014) Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget 5(13):4651–4664
8. van Herpen CM, van der Voort R, van der Laak JA, Klasen IS, de Graaf AO, van Kempen LC, de Vries IJ, Boer TD, Dolstra H, Torensma R, van Krieken JH, Adema GJ, De Mulder PH (2008) Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer 123(10):2354–2361. doi:10.1002/ijc.23756
9. Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N (2012) Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 72(16):3997–4007. doi:10.1158/0008-5472.CAN-12-1377
10. Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T (2013) Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Res Treat 137(2):407–416. doi:10.1007/s10549-012-2356-2
11. Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, Serody JS (2014) Prognostic B-cell signatures using mRNA-Seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 20(14):3818–3829. doi:10.1158/1078-0432.CCR-13-3368
12. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Muller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenfuhrer J, Hengstler JG (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18(9):2695–2703. doi:10.1158/1078-0432.CCR-11-2210
13. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF (2004) Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15(7):1109–1114. doi:10.1093/annonc/mdh280
14. Barbera-Guillem E, Nelson MB, Barr B, Nyhus JK, May KF Jr, Feng L, Sampsel JW (2000) B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 48(10):541–549
15. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mule A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29(7):814–824. doi:10.1200/JCO.2010.28.9777
16. Brodt P, Gordon J (1978) Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol 121(1):359–362
17. Brodt P, Gordon J (1982) Natural resistance mechanisms may play a role in protection against chemical carcinogenesis. Cancer Immunol Immunother 13(2):125–127
18. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4(5):627–630
19. Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM (2004) Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27(4):273–281
20. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH, Rosenblatt JD (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117(4):574–586. doi:10.1002/ijc.21177
21. Zhang Y, Morgan R, Podack ER, Rosenblatt J (2013) B cell regulation of anti-tumor immune response. Immunol Res 57(1–3):115–124. doi:10.1007/s12026-013-8472-1
22. Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, Rosenblatt JD (2013) B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother 62(1):87–99. doi:10.1007/s00262-012-1313-6
23. Inoue S, Leitner WW, Golding B, Scott D (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Res 66(15):7741–7747. doi:10.1158/0008-5472.CAN-05-3766
24. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM (2014) B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 25(6):809–821. doi:10.1016/j.ccr.2014.04.026
25. Linton PJ, Harbertson J, Bradley LM (2000) A critical role for B cells in the development of memory CD4 cells. J Immunol 165(10):5558–5565
26. Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y (2001) Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 13(12):1583–1593
27. Nelson BH (2010) CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185(9):4977–4982. doi:10.4049/jimmunol.1001323
28. Linton PJ, Bautista B, Biederman E, Bradley ES, Harbertson J, Kondrack RM, Padrick RC, Bradley LM (2003) Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med 197(7):875–883. doi:10.1084/jem.20021290
29. Schultz KR, Klarnet JP, Gieni RS, HayGlass KT, Greenberg PD (1990) The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science 249(4971):921–923
30. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M (2000) B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 192(4):475–482
31. Kim SJ, Caton M, Wang C, Khalil M, Zhou ZJ, Hardin J, Diamond B (2008) Increased IL-12 inhibits B cells’ differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts. J Exp Med 205(10):2437–2448. doi:10.1084/jem.20070731
32. Joao C, Ogle BM, Gay-Rabinstein C, Platt JL, Cascalho M (2004) B cell-dependent TCR diversification. J Immunol 172(8):4709–4716
33. Crowley MT, Reilly CR, Lo D (1999) Influence of lymphocytes on the presence and organization of dendritic cell subsets in the spleen. J Immunol 163(9):4894–4900
34. + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184(7):4006–4016. doi:10.4049/jimmunol.0903009
35. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino P, Arra C, Cicala C, Pinto A, Morello S (2012) Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol 189(5):2226–2233. doi:10.4049/jimmunol.1200744
36. Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, Kroeger KM, Dunn R, Martins G, Lowenstein PR, Castro MG (2011) B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 13(10):947–960
37. Naslund TI, Gehrmann U, Qazi KR, Karlsson MC, Gabrielsson S (2013) Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol 190(6):2712–2719. doi:10.4049/jimmunol.1203082
38. Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, Blouin A, Kaiser LR, Albelda SM (2008) B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother 31(5):446–457. doi:10.1097/CJI.0b013e31816d1d6a
39. DiLillo DJ, Matsushita T, Tedder TF (2010) B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 1183:38–57. doi:10.1111/j.1749-6632.2009.05137.x
40. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA 108(26):10662–10667. doi:10.1073/pnas.1100994108
41. Horikawa M, Minard-Colin V, Matsushita T, Tedder TF (2011) Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest 121(11):4268–4280. doi:10.1172/JCI59266
42. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A (2011) Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res 71(10):3505–3515. doi:10.1158/0008-5472.CAN-10-4316
43. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464(7286):302–305. doi:10.1038/nature08782
44. Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M (2013) An IKKalpha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev 27(13):1435–1440. doi:10.1101/gad.220202.113
45. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M (2015) Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521(7550):94–98. doi:10.1038/nature14395
46. Collins AM, Jackson KJ (2013) A Temporal model of human IgE and IgG antibody function. Front Immunol 4:235. doi:10.3389/fimmu.2013.00235
47. Chaudhuri J, Alt FW (2004) Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol 4(7):541–552. doi:10.1038/nri1395
48. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Correa I, Roberts L, Beddowes E, Koers A, Hobbs C, Ferreira S, Geh JL, Healy C, Harries M, Acland KM, Blower PJ, Mitchell T, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN (2013) IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 123(4):1457–1474. doi:10.1172/JCI65579
49. Daveau M, Pavie-Fischer J, Rivat L, Rivat C, Ropartz C, Peter HH, Cesarini JP, Kourilsky FM (1977) IgG4 subclass in malignant melanoma. J Natl Cancer Inst 58(2):189–192
50. Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, Mueller CM, Zenilman ME, Bluth MH (2008) Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 153(3):401–409. doi:10.1111/j.1365-2249.2008.03726.x
51. Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape K, Lamborn KR, Parsa AT, Sison JD, Prados MD (2006) Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 66(8):4531–4541. doi:10.1158/0008-5472.CAN-05-4032
52. + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 163(5):2944–2952
53. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58(10):1535–1544. doi:10.1007/s00262-009-0733-4
54. + helper T cell responses in cancer patients. Blood 106(3):1008–1011. doi:10.1182/blood-2005-02-0607
55. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103(1):97–100. doi:10.1002/ijc.10801
56. Zornig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmuller SB, Jager D (2015) Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer 136(1):138–151. doi:10.1002/ijc.28980
57. Yamaguchi T, Takii Y, Maruyama S (2014) Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today 44(8):1529–1535. doi:10.1007/s00595-013-0703-5
58. + T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 108(40):16723–16728. doi:10.1073/pnas.1110814108
59. Hara I, Takechi Y, Houghton AN (1995) Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 182(5):1609–1614
60. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753):1510–1512. doi:10.1126/science.1118948
61. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Di Santo JP, Lowell CA, Bruhns P (2013) Neutrophils mediate antibody-induced antitumor effects in mice. Blood 122(18):3160–3164. doi:10.1182/blood-2013-04-497446
62. Patel D, Bassi R, Hooper AT, Sun H, Huber J, Hicklin DJ, Kang X (2008) Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies. Anticancer Res 28(5A):2679–2686
63. Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE (2009) In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 183(5):3195–3203. doi:10.4049/jimmunol.0803773
64. Zhang J, Yang JM, Wang HJ, Ru GQ, Fan DM (2013) Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo. PLoS One 8(1):e52940. doi:10.1371/journal.pone.0052940
65. Ly LV, Sluijter M, van der Burg SH, Jager MJ, van Hall T (2013) Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. J Immunol 190(1):489–496. doi:10.4049/jimmunol.1200135
66. Yong L, Huiyong Z, Jing H, Huaqian W, Xiangbing H, Yanjun M, Xiaoyu G, Li H, Yanan Y, Rongyue C, Hao F, Jingjing L, Jie W (2010) Vaccination with a potent DNA vaccine targeting B-cell epitopes of hGRP induces prophylactic and therapeutic antitumor activity in vivo. Gene Ther 17(4):459–468. doi:10.1038/gt.2009.165
67. Patel SP, Bristol A, Saric O, Wang XP, Dubeykovskiy A, Arlen PM, Morse MA (2013) Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. Cancer Immunol Immunother 62(6):1011–1019. doi:10.1007/s00262-013-1420-z
68. Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, Dodev T, Koers A, Blower PJ, Corrigan C, Beavil AJ, Spicer JF, Nestle FO, Gould HJ (2012) Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother 61(9):1547–1564. doi:10.1007/s00262-011-1162-8
69. Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L (2009) Antitumor IgE adjuvanticity: key role of Fc epsilon RI. J Immunol 183(7):4530–4536. doi:10.4049/jimmunol.0900842
70. Daniels-Wells TR, Helguera G, Leuchter RK, Quintero R, Kozman M, Rodriguez JA, Ortiz-Sanchez E, Martinez-Maza O, Schultes BC, Nicodemus CF, Penichet ML (2013) A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer 13:195. doi:10.1186/1471-2407-13-195
71. Sorrentino R, Morello S, Forte G, Montinaro A, De Vita G, Luciano A, Palma G, Arra C, Maiolino P, Adcock IM, Pinto A (2011) B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med 183(10):1369–1379. doi:10.1164/rccm.201010-1738OC
72. Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S, Chang AE (2011) ADOPTIVE transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 17:4987–4995. doi:10.1158/1078-0432.CCR-11-0207
73. Ma Y, Xiang D, Sun J, Ding C, Liu M, Hu X, Li G, Kloecker G, Zhang HG, Yan J (2013) Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J Immunol 190(11):5588–5599. doi:10.4049/jimmunol.1203216
74. Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodriguez JA, Martinez-Maza O, Schultes BC, Nicodemus CF, Penichet ML (2012) Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother 61(7):991–1003. doi:10.1007/s00262-011-1150-z
75. Pearce OM, Laubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A (2014) Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci USA 111(16):5998–6003. doi:10.1073/pnas.1209067111
76. de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7(5):411–423. doi:10.1016/j.ccr.2005.04.014
77. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, Naldini L, de Visser KE, De Palma M, Coussens LM (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17(2):121–134. doi:10.1016/j.ccr.2009.12.019
78. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16(2):91–102. doi:10.1016/j.ccr.2009.06.018
79. Zhang M, Wang Z, Graner MW, Yang L, Liao M, Yang Q, Gou J, Zhu Y, Wu C, Liu H, Zhou B, Chen X (2011) B cell infiltration is associated with the increased IL-17 and IL-22 expression in the lungs of patients with tuberculosis. Cell Immunol 270(2):217–223. doi:10.1016/j.cellimm.2011.05.009